Divya Ramchandani

About Divya Ramchandani

I\'m a translational scientist with 10+ years of experience unraveling the molecular underpinnings of solid tumors, and I thrive at the intersection of science, strategy, and innovation. From dissecting the metabolic vulnerabilities of triple-negative breast cancer to designing high-throughput assays and leading cross-functional collaborations, I’ve built a career rooted in curiosity and impact.I contribute to oncology drug development by identifying biomarkers, integrating multi-omics data, supporting preclinical and clinical teams to inform indication selection and mechanism-of-action hypotheses. I bring not just technical fluency across genomics, proteomics, and gene editing—but also a big-picture mindset focused on translating research into meaningful therapies for patients.My strength lies in combining scientific depth with strategic thinking. I love diving into emerging trends—whether it\'s novel modalities, tumor microenvironment insights, or cutting-edge translational tools—and translating that complexity into clear narratives that inform cross-disciplinary decision-making.I thrive in fast-paced, matrixed environments where big questions need thoughtful, data-driven answers. Whether it\'s crafting a biomarker strategy, assessing external innovation, or communicating findings to diverse stakeholders, I bring a solutions-focused, go-getter mindset to every challenge.Let’s connect if you’re passionate about driving smarter, more innovative science to help patients faster.

Experience

1. Scientific Lead, Translational Sciences

   Eli Lilly and Company

   Jun 2023 — Present · New York, NY, US

   Engineered high-throughput, quantitative mammalian cell-based assays, enabling functional readouts that accelerated preclinical oncology candidate selection-Led design and execution of compound profiling studies to evaluate efficacy, identify synergistic drug combinations, and uncover mechanisms of resistance in solid tumors-Discovered and validated novel signaling nodes within oncogenic pathways, directly informing combination therapy strategies and resistance-overcoming approaches-Scouted and integrated cutting-edge technologies and external vendors, enhancing platform capabilities and streamlining experimental workflows-Synthesized complex molecular pathway data into actionable insights, influencing therapeutic strategy and supporting cross-functional translational research teams.

Education

• University of Cincinnati

  Doctor of Philosophy (Ph.D.), Pharmaceutical Sciences

  2010 — 2015

• Delhi University

  Bachelor of Pharmacy - BPharm, Pharmaceutical Sciences

  2006 — 2010